{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-10-23",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "discontinued_date": "04/28/2026",
      "update_type": "New",
      "initial_posting_date": "04/28/2026",
      "package_ndc": "70370-5025-1",
      "generic_name": "Crinecerfont Capsule",
      "contact_info": "858-617-7600",
      "related_info": "Neurocrine is discontinuing only the 25 mg soft gel capsule dose strength (NDC 70370-5025-01). The 50mg and 100mg soft gel capsule dose strength (NDC 70370-5050-1 and 70370-5100-1), and 50 mg/mL oral solution will continue to be marketed (NDC 70370-5250-1).",
      "update_date": "04/28/2026",
      "therapeutic_category": [
        "Endocrinology/Metabolism"
      ],
      "dosage_form": "Capsule",
      "presentation": "Crenessity, Capsule, 25 mg (NDC 70370-5025-1)",
      "company_name": "Neurocrine Biosciences, Inc.",
      "status": "To Be Discontinued"
    }
  ]
}